Company: BSX
Filing Date: 2025-02-18
Form Type: S-3ASR
Source: 0001104659-25-014808
Chunk: 3

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-18
Form: S-3ASR
Chunk 3
---
OSTON SCIENTIFIC CORPORATION        | ​ | ​ | ​    | ​ |  5 | ​ | ​ |
| AMERICAN MEDICAL SYSTEMS EUROPE B.V. | ​ | ​ | ​    | ​ |  5 | ​ | ​ |
| USE OF PROCEEDS                      | ​ | ​ | ​    | ​ |  6 | ​ | ​ |
| DESCRIPTION OF DEBT SECURITIES       | ​ | ​ | ​    | ​ |  7 | ​ | ​ |
| PLAN OF DISTRIBUTION                 | ​ | ​ | ​    | ​ | 19 | ​ | ​ |
| LEGAL MATTERS                        | ​ | ​ | ​    | ​ | 21 | ​ | ​ |
| EXPERTS                              | ​ | ​ | ​    | ​ | 21 | ​ | ​ |

i

TABLE OF CONTENTS

### ABOUT THIS PROSPECTUS
Unless otherwise indicated or unless the context otherwise requires, all references in this prospectus to the “Company,” “we,” “us,” and “our” refer, collectively, to Boston Scientific Corporation and its consolidated subsidiaries and/or, where applicable, only to American Medical Systems Europe B.V. as an issuer of debt securities; the term “Boston Scientific” refers to Boston Scientific Corporation, a Delaware corporation; and the term “AMS Europe” refers to American Medical Systems Europe B.V., a private company with limited liability ( besloten vennootschap met beperkte aansprakelijkheid ) incorporated under the laws of the Netherlands. This prospectus is part of a registration statement that we filed with the United States Securities and Exchange Commission, or SEC, using the “shelf” registration process. Under this shelf process, Boston Scientific, AMS Europe and/or any other subsidiary of Boston Scientific that may be designated by post-effective amendment as an issuer of the debt securities under the indenture from time to time may sell the securities described in this prospectus in one or more offerings. This prospectus provides you with a general description of the securities Boston Scientific, AMS Europe and/or any other subsidiary of Boston Scientific that may be designated by post-effective amendment as an issuer of the debt securities under the indenture from time to time may offer. Each time Boston Scientific, AMS Europe and/or any other subsidiary of Boston Scientific that may be designated by post-effective amendment as an issuer of the debt securities under the indenture from time to time sell securities, we will provide a prospectus supplement, which may be